Finance

Lists
Why is 600664 up 4.91%?
Dive Deeper
600664:SHA
Harbin Pharmaceutical Group Co Ltd
CN¥5.55
+4.91%
(+0.26) 1D
Oct 30, 3:00:02 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600664...
Open
CN¥5.20
High
CN¥5.82
Low
CN¥5.04
Mkt. cap
13.98B
Avg. vol.
344.13M
Volume
405.30M
P/E ratio
22.07
52-wk high
CN¥9.86
52-wk low
CN¥2.84
EPS
CN¥0.25
Shares outstanding
2.54B
No. of employees
10K
Open
CN¥5.20
High
CN¥5.82
Low
CN¥5.04
Mkt. cap
13.98B
Avg. vol.
344.13M
Volume
405.30M
P/E ratio
22.07
52-wk high
CN¥9.86
52-wk low
CN¥2.84
EPS
CN¥0.25
Shares outstanding
2.54B
No. of employees
10K
News stories
From web sources and news partners
Profile
Harbin Pharmaceutical Group Co., Ltd. is a Chinese partially state-owned company engaged in the research & development, manufacture, and sale of pharmaceutical products. HPGC medication offerings include traditional Chinese medicine and biopharmaceuticals; its main offerings include antibiotics, including amoxicillin and penicillin, and dietary supplements, including zinc gluconate and calcium gluconate. The company owns both Renmintongtai, a drugstore chain and medical wholesaler for the domestic market, and GNC, a U.S.-based international retailer of supplements and wellness products. Wikipedia
About Harbin Pharmaceutical Group Co Ltd
CEO-
Employees10K
Founded1988
Headquarters-
SectorPharmaceutical industry
Websitehayao.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
3.94B
4.18B
4.12B
4.06B
Cost of goods sold
2.96B
3.17B
2.96B
2.99B
Cost of revenue
2.96B
3.17B
2.96B
2.99B
Research and development expenses
51.31M
27.02M
33.38M
31.45M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
815.96M
721.16M
803.44M
721.99M
Operating expense
897.00M
786.62M
895.87M
725.79M
Total operating expenses
3.85B
3.96B
3.86B
3.71B
Operating income
88.76M
219.91M
264.89M
344.55M
Other non operating income
-13.01M
-7.97M
1.21M
-61.88M
EBT including unusual items
91.70M
206.43M
311.43M
263.84M
EBT excluding unusual items
63.73M
208.13M
254.28M
298.65M
Income tax expense
34.62M
45.36M
63.42M
53.67M
Effective tax rate
37.75%
21.97%
20.37%
20.34%
Other operating expenses
29.19M
21.94M
53.95M
-6.05M
Net income
33.00M
161.13M
249.19M
189.91M
Net profit margin
0.84%
3.86%
6.05%
4.68%
Earnings per share
-
-
-
-
Interest and investment income
3.14M
4.20M
6.12M
18.11M
Interest expense
-10.76M
-8.01M
-10.10M
-9.97M
Net interest expenses
-7.62M
-3.81M
-3.98M
8.15M
Depreciation and amortization charges
-
-
-
-
EBITDA
143.03M
274.17M
320.66M
398.82M
Gain or loss from assets sale
-3.83M
-
-35.83M
35.83M
Upcoming events
AI content may include mistakes. Learn more
Google apps